Xeris Biopharma reported an 81% year-over-year increase in Recorlev revenue during the second quarter of 2026 as growing patient demand drove portfolio-wide product growth and the company strengthened intellectual property protection around Keveyis.
Recorlev net revenue reached approximately $56.8 million, up from $31.4 million in the prior-year quarter. Net product revenue increased 34% to $91 million, while total revenue increased 29% to $92.1 million.
The company attributed the growth primarily to increased patient demand for Recorlev, its treatment for endogenous Cushing’s syndrome. Strategic commercial investments made earlier in 2026 are beginning to gain traction, with management expecting a larger contribution during the second half.
Xeris also received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering the use of Keveyis. Once issued, the patent is expected to extend intellectual property protection for the primary periodic paralysis treatment through at least 2039.
Gross margin improved to 86% from 82% a year earlier, primarily due to favorable product mix. Adjusted EBITDA increased by $6.7 million year-over-year to $19.3 million.
Xeris tightened its full-year 2026 revenue outlook to $385 million to $390 million following the strong first-half performance.
The company’s development pipeline is also advancing. XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, received its second U.S. patent in July. Xeris expects its Phase 3 trial to begin later in 2026.
KEY QUOTES:
“The second quarter was another strong period for Xeris, with net product revenue growing 34% year-over-year, driven by Recorlev’s exceptional commercial momentum.”
“Beyond our commercial execution, the second quarter also brought an important strategic milestone. We received a Notice of Allowance from the United States Patent and Trademark Office for a new Keveyis patent expected to extend intellectual property protection through at least 2039.”
John Shannon, Chairman and CEO of Xeris
